CliffBio
small molecule

OMLONTI

OMIDENEPAG ISOPROPYL

Loss of exclusivityJuly 2039latest FDA-listed patent expiry
CompanyOCUVEX THERAPEUTICS INC

Drug detail

Brand nameOMLONTI
Active ingredientOMIDENEPAG ISOPROPYL
Strength0.002%
Dosage formSOLUTION
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalSeptember 2022
Marketing statusRX

Listed patents

PatentExpiresType
11666563July 2039use U-3454
12290511December 2038use U-3454
10774072June 2035substance
10702511January 2035product
10179127January 2035product
9415038January 2035product
RE48183January 2035product
11793798January 2035product
10765750January 2035product
12295946January 2035product
11197849January 2035product
8685986October 2029product
8648097October 2029substance, product

Regulatory exclusivity

CodeExpires
NCESeptember 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.